OBJECTIVE: To evaluate the impact of year of surgery on clinical, pathological and oncological outcomes of patients with high-risk prostate cancer. PATIENTS AND METHODS: We evaluated 1 033 patients with clinically high-risk prostate cancer, defined as the presence of at least one of the following risk factors: preoperative prostate-specific antigen (PSA) level >20 ng/mL, and/or clinical stage ≥T3, and/or biopsy Gleason score ≥8. Patients were treated between 1990 and 2013 at a single institution. The year-by-year trends in clinical and pathological characteristics were examined. Multivariable Cox regression analysis was used to test the relationship between year of surgery and oncological outcomes. RESULTS: We observed a decrease over time in the proportion of patients with high-risk disease (preoperative PSA >20 ng/mL or clinical stage cT3). A trend in the opposite direction was seen for biopsy Gleason score ≥8 tumours. We observed a considerable increase in the median number of lymph nodes removed, which was associated with an increased rate of lymph node invasion (LNI). On multivariable Cox regression analysis, year of surgery was associated with a reduced risk of biochemical recurrence (hazard ratio [HR] per 5-year interval 0.90, 95% confidence interval [CI] 0.84-0.96; P = 0.01) and distant metastasis (HR per 5-year interval 0.91, 95% CI 0.83-0.99; P = 0.039), after adjusting for age, preoperative PSA, pathological stage, LNI, surgical margin status, and pathological Gleason score. CONCLUSIONS: In this single-centre study, an increased diagnosis of localized and less extensive high-grade prostate cancer was observed over the last two decades. Patients with high-risk disease who were selected for radical prostatectomy showed better cancer control over time. Better definitions of what constitutes high-risk prostate cancer among contemporary patients are needed.
OBJECTIVE: To evaluate the impact of year of surgery on clinical, pathological and oncological outcomes of patients with high-risk prostate cancer. PATIENTS AND METHODS: We evaluated 1 033 patients with clinically high-risk prostate cancer, defined as the presence of at least one of the following risk factors: preoperative prostate-specific antigen (PSA) level >20 ng/mL, and/or clinical stage ≥T3, and/or biopsy Gleason score ≥8. Patients were treated between 1990 and 2013 at a single institution. The year-by-year trends in clinical and pathological characteristics were examined. Multivariable Cox regression analysis was used to test the relationship between year of surgery and oncological outcomes. RESULTS: We observed a decrease over time in the proportion of patients with high-risk disease (preoperative PSA >20 ng/mL or clinical stage cT3). A trend in the opposite direction was seen for biopsy Gleason score ≥8 tumours. We observed a considerable increase in the median number of lymph nodes removed, which was associated with an increased rate of lymph node invasion (LNI). On multivariable Cox regression analysis, year of surgery was associated with a reduced risk of biochemical recurrence (hazard ratio [HR] per 5-year interval 0.90, 95% confidence interval [CI] 0.84-0.96; P = 0.01) and distant metastasis (HR per 5-year interval 0.91, 95% CI 0.83-0.99; P = 0.039), after adjusting for age, preoperative PSA, pathological stage, LNI, surgical margin status, and pathological Gleason score. CONCLUSIONS: In this single-centre study, an increased diagnosis of localized and less extensive high-grade prostate cancer was observed over the last two decades. Patients with high-risk disease who were selected for radical prostatectomy showed better cancer control over time. Better definitions of what constitutes high-risk prostate cancer among contemporary patients are needed.
Authors: Fernando J Bianco; Andrew J Vickers; Angel M Cronin; Eric A Klein; James A Eastham; J Edson Pontes; Peter T Scardino Journal: J Urol Date: 2010-01-18 Impact factor: 7.450
Authors: Ofer Yossepowitch; Scott E Eggener; Angel M Serio; Brett S Carver; Fernando J Bianco; Peter T Scardino; James A Eastham Journal: Eur Urol Date: 2007-10-12 Impact factor: 20.096
Authors: Stacy Loeb; Edward M Schaeffer; Bruce J Trock; Jonathan I Epstein; Elizabeth B Humphreys; Patrick C Walsh Journal: Urology Date: 2009-11-22 Impact factor: 2.649
Authors: F Abdollah; N Suardi; A Gallina; M Bianchi; M Tutolo; N Passoni; N Fossati; M Sun; P dell'Oglio; A Salonia; P I Karakiewicz; P Rigatti; F Montorsi; A Briganti Journal: Ann Oncol Date: 2013-03-18 Impact factor: 32.976
Authors: Firas Abdollah; Giorgio Gandaglia; Nazareno Suardi; Umberto Capitanio; Andrea Salonia; Alessandro Nini; Marco Moschini; Maxine Sun; Pierre I Karakiewicz; Sharhokh F Shariat; Francesco Montorsi; Alberto Briganti Journal: Eur Urol Date: 2014-06-02 Impact factor: 20.096
Authors: Michael R Abern; Martha K Terris; William J Aronson; Christopher J Kane; Christopher L Amling; Matthew R Cooperberg; Stephen J Freedland Journal: Cancer Date: 2014-03-19 Impact factor: 6.860
Authors: Maxine M Chen; Jaquelyn L Jahn; John R Barber; Misop Han; Meir J Stampfer; Elizabeth A Platz; Kathryn L Penney Journal: PLoS One Date: 2020-06-11 Impact factor: 3.240
Authors: Rocco S Flammia; Benedikt Hoeh; Gabriele Sorce; Francesco Chierigo; Lukas Hohenhorst; Zhen Tian; Jordan A Goyal; Costantino Leonardo; Alberto Briganti; Markus Graefen; Carlo Terrone; Fred Saad; Shahrokh F Shariat; Francesco Montorsi; Felix K H Chun; Michele Gallucci; Pierre I Karakiewicz Journal: Prostate Date: 2022-04-11 Impact factor: 4.012